Time-course of alterations of high density lipoproteins (HDL) during thyroxine administration to hypothyroid women

Verdugo, Cesar; Perrot, L; Ponsin, Gabriel

doi:10.1016/0378-5122(88)90169-7

Cited by 11 publications

(15 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reduction was larger in individuals with higher pre-treatment cholesterol levels and in hypothyroid individuals previously taking suboptimal T4 doses 34 . Serum HDL cholesterol levels tend to decrease with thyroid replacement, but this is a less consistent finding 35 . Serum Lp(a) levels also tend to decrease with restoration of euthyroidism 11,23 .…”

Section: Hypothyroidismmentioning

confidence: 77%

Dyslipidemia in patients with thyroid disorders

Liberopoulos¹,

Elisaf²

2002

View full text Add to dashboard Cite

Thyroid disorders are known to influence lipid metabolism and are common in dyslipidemic patients. Overt and subclinical hypothyroidism have an adverse effect on the serum lipid profile that may predispose to the development of atherosclerotic disease. Although thyroid substitution therapy is beneficial for patients with overt hypothyroidism, the question of whether subclinical hypothyroidism must be treated remains unanswered. The association between thyroid autoimmunity and lipoprotein (a) levels is controversial. Hyperthyroidism may be the underlying cause for acquired hypocholesterolemia or unexpected improvement of the lipid profile of a previously hyperlipidemic patient.

show abstract

Section: Hypothyroidismmentioning

confidence: 77%

Dyslipidemia in patients with thyroid disorders

Liberopoulos¹,

Elisaf²

2002

View full text Add to dashboard Cite

show abstract

“…As expected (Agdeppa et al ., 1979; Muls et al ., 1984; Friis & Pedersen, 1987; Verdugo et al ., 1987; O’Brien et al ., 1997), and as compared to normolipidaemic controls, hypothyroidism was associated with significant alterations of the serum lipoprotein profile, including elevated total cholesterol, triglyceride, HDL cholesterol, HDL size, LDL cholesterol, apo B, apo A‐I and apo A‐II. Lipoprotein abnormalities tended to be corrected by L‐T 4 therapy, most of them being actually normalized after 2 months of treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Hypothyroidism is accompanied by premature appearance of coronary artery disease, and a number of abnormalities in lipoprotein metabolism, including significant increases in serum levels of total cholesterol, triglycerides, very low‐density lipoprotein (VLDL) cholesterol, low‐density lipoprotein (LDL) cholesterol, high‐density lipoprotein (HDL) cholesterol (mainly HDL 2 ) and apolipoproteins B and A‐I (Agdeppa et al ., 1979; Muls et al ., 1984; Friis & Pedersen, 1987; Verdugo et al ., 1987; O’Brien et al ., 1997). Reduced activities of the LDL receptor and scavenger receptor pathways were proposed to account, at least in part, for the accumulation of apo B‐containing lipoproteins in plasma from hypothyroid patients (Chait et al ., 1979; Thompson et al ., 1981; Staels et al ., 1990).…”

mentioning

confidence: 99%

Low cholesteryl ester transfer protein (CETP) concentration but normal CETP activity in serum from patients with short‐term hypothyroidism Lack of relationship to lipoprotein abnormalities

Dedecjus

Masson

Gautier

et al. 2003

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…The extent of these changes depends both on the severity and duration of the thyroid dysfunction and on the degree of pretreatment hypercholesterolemia (13)(14)(15). Diet, body weight, and smoking habits can also modify absolute LDL-C levels (16,17).…”

mentioning

confidence: 99%

Changes in Plasma Low-Density Lipoprotein (LDL)- and High-Density Lipoprotein Cholesterol in Hypo- and Hyperthyroid Patients Are Related to Changes in Free Thyroxine, Not to Polymorphisms in LDL Receptor or Cholesterol Ester Transfer Protein Genes

Diekman

Anghelescu

Endert

et al. 2000

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

Thyroid function disorders lead to changes in lipoprotein metabolism. Both plasma low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) increase in hypothyroidism and decrease in hyperthyroidism. Changes in LDL-C relate to altered clearance of LDL particles caused by changes in expression of LDL receptors on liver cell surfaces. Changes in cholesterol ester transfer activity partly explain changes in HDL-C. It has been suggested that the magnitude of these changes is related to polymorphisms of involved genes. The aim of the present study is to investigate whether the polymorphic AvaII restriction site in exon 13 of the LDL receptor gene and the polymorphic TaqIB site in intron 1 of the cholesterol ester transfer protein are associated with the magnitude of the changes in plasma LDL-C and HDL-C, respectively, in the transition from the hypo- or hyperthyroid to the euthyroid state. From a consecutive group of 66 untreated hypothyroid and 60 hyperthyroid patients, 47 Caucasians in each group were analyzed. Fasting LDL-C and HDL-C were measured at baseline and 3 months after restoration of the euthyroid state. Genotype was determined by means of PCR techniques. The homozygous presence of a restriction site was designated as +/+, heterozygous as +/-, and absence as -/-. Trend analysis was done with ANOVA. Among hypo- or hyperthyroid patients, subgroups with different genotypes did not differ in thyroid function pre- or post treatment. The mean decrease in LDL-C (mmol/L +/- SD) in hypothyroid patients with different AvaII genotypes did not differ: - 1.07 +/- 1.44 (-/-, N = 15), -1.25 +/- 1.53 (+/-, N = 19), and -1.18 +/- 1.01 (+/+, N = 13) mmol/L [not significant (NS)]; neither did the mean increase in hyperthyroid patients: 1.07 +/- 0.90 (-/-, N = 18), 0.92 +/- 1.00 (+/-, N = 21), and 1.20 +/- 0.45 (+/+, N = 6) (NS). The mean decrease in HDL-C (mmol/L +/- SD) in hypothyroid patients with different TaqIB genotypes did not differ: -0.22 +/- 0.26 (-/-, N = 13), -0.15 +/- 0.23 (+/-, N = 21), and -0.12 +/- 0.22 (+/+, N = 9) (NS); neither did the mean increase in hyperthyroid patients: 0.29 +/- 0.39 (-/-, N = 7), 0.26 +/- 0.23 (+/-, N = 22), and 0.19 +/- 0.31 (+/+, N = 18) (NS). Changes in LDL-C and HDL-C correlated with the logarithm of the change in free T4 (fT4), expressed as the fT4 posttreatment/fT4 pretreatment ratio (r = -0.81, P < 0.001; and r = -0.62, P < 0.001, respectively). In conclusion, in the transition from hypo- or hyperthyroidism to euthyroidism, no association is found between AvaII genotype and changes in plasma LDL-C nor between TaqIB genotype and changes in HDL-C. Changes in LDL-C and HDL-C correlate with changes in fT4.

show abstract

Time-course of alterations of high density lipoproteins (HDL) during thyroxine administration to hypothyroid women

Cited by 11 publications

References 1 publication

Dyslipidemia in patients with thyroid disorders

Dyslipidemia in patients with thyroid disorders

Low cholesteryl ester transfer protein (CETP) concentration but normal CETP activity in serum from patients with short‐term hypothyroidism Lack of relationship to lipoprotein abnormalities

Changes in Plasma Low-Density Lipoprotein (LDL)- and High-Density Lipoprotein Cholesterol in Hypo- and Hyperthyroid Patients Are Related to Changes in Free Thyroxine, Not to Polymorphisms in LDL Receptor or Cholesterol Ester Transfer Protein Genes

Contact Info

Product

Resources

About